<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03518528</url>
  </required_header>
  <id_info>
    <org_study_id>PATCHS2018</org_study_id>
    <nct_id>NCT03518528</nct_id>
  </id_info>
  <brief_title>Comparison of Vaginal and Transdermal Oestrogen Before Frozen Thawed Embryo Transfer</brief_title>
  <official_title>Endometrial Estrogen Preparation Before Frozen-thawed Embryo Transfer : Comparison of Vaginal and Transdermal Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare pregnancy outcomes of frozen-thawed embryo transfer&#xD;
      after endometrial preparation with vaginal estradiol or transdermal estradiol and to evaluate&#xD;
      women's satisfaction&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Frozen-thawed transfer embryo are more and more frequent but to date, there is no consensus&#xD;
      on the ideal management of the adequate endometrial preparation.&#xD;
&#xD;
      Artificial preparation of endometrium is commonly used in assisted reproduction center&#xD;
      because it is more easy to schedule.&#xD;
&#xD;
      Estradiol could be administrate by oral, vaginal or transdermal, but no protocol seems to&#xD;
      improve clinical pregnancy rates.&#xD;
&#xD;
      To investigator's knowledge, transdermal estradiol has never been compare to vaginal&#xD;
      administration before frozen-thawed embryo transfer.&#xD;
&#xD;
      Because transdermal administration could improve satisfaction of patients and reduce duration&#xD;
      of treatment (when compare to oral administration), the investigators conduct a prospective&#xD;
      study to compare clinical pregnancy rate after transdermal or vaginal estradiol&#xD;
      administration to prepare the endometrium before frozen-thawed embryo transfer.&#xD;
&#xD;
      The investigator also evaluate side effects and patients satisfaction in both protocol.&#xD;
&#xD;
      The patients choose if they prefer vaginal or transdermal protocol after receiving sufficient&#xD;
      information during medical consultation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">August 30, 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>clinical pregnancy</measure>
    <time_frame>12 weeks</time_frame>
    <description>defined as fetal cardiac activity at 12 weeks of gestation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>chemical pregnancy</measure>
    <time_frame>6 weeks</time_frame>
    <description>Defined as serum HCG levels &gt;10 IU/L, 14 days after the embryo transfer, followed by a rapid decrease until being undetectable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>spontaneous pregnancy loss</measure>
    <time_frame>12 weeks</time_frame>
    <description>Including early and late pregnancy losses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasmatic estradiol concentration on the day of transfer</measure>
    <time_frame>21 days</time_frame>
    <description>plasmatic estradiol concentration on the day of transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasmatic lh concentration on the day of transfer</measure>
    <time_frame>21 days</time_frame>
    <description>plasmatic lh concentration on the day of transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasmatic progesterone concentration on the day of transfer</measure>
    <time_frame>21 days</time_frame>
    <description>plasmatic progesterone concentration on the day of transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endometrial thickness</measure>
    <time_frame>21 days</time_frame>
    <description>sonographic measurement of endometrial thickness on the day of transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>annulation</measure>
    <time_frame>21 days</time_frame>
    <description>defined when transfer is cancel if endometrial thickness is too thick (&gt;6-7mm), when spontaneous ovulation is found with progesterone plasmatic increase and corpus luteum is seen by sonography or when unpredictable events occur (infections, ZIKA suspicion, endometriosis crisis, bad observance…). Annulation could be decided by biologist in case of embryo's lysis or bad quality seen after thawing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment duration</measure>
    <time_frame>21 days</time_frame>
    <description>duration of treatment before transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>satisfaction evaluated by anonymous survey the day of transfer</measure>
    <time_frame>1 month</time_frame>
    <description>evaluated by anonymous survey the day of transfer</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Embryo Transfer</condition>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>transdermal</arm_group_label>
    <description>transdermal estradiol (Vivelledot, Novartis) 100 µg on day 3, then 200 µg day 7 and every 4 days, until first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vaginal</arm_group_label>
    <description>Vaginal estradiol (Provames, Sanofi) 4mg per day from day 3 to first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol 2 MG</intervention_name>
    <description>Vaginal estradiol (Provames, Sanofi) 4mg per day from day 3 to first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks</description>
    <arm_group_label>vaginal</arm_group_label>
    <other_name>provames 2mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol 100 µg</intervention_name>
    <description>transdermal estradiol (Vivelledot, Novartis) 100 µg on day 3, then 200 µg day 7 and every 4 days, until first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks.</description>
    <arm_group_label>transdermal</arm_group_label>
    <other_name>vivelledot 100 µg</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients follow in our assisted reprodution unit, requesting frozen-thawed embryo transfer&#xD;
        after ivf or icsi&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age ≥ 18 and &lt;43&#xD;
&#xD;
          -  frozen-thawed embryo transfer after exogenously administered estrogen in either way&#xD;
             transdermal or vaginal&#xD;
&#xD;
          -  patients who accepted being included and signed the consent forms.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient who refuse to participate&#xD;
&#xD;
          -  frozen-thawed embryotransfer after stimulated or natural cycle&#xD;
&#xD;
          -  oocyte or sperm donation&#xD;
&#xD;
          -  endometrial thickness after 21 days &lt;6mm&#xD;
&#xD;
          -  non-french speaking patients&#xD;
&#xD;
          -  women under legal guardianship&#xD;
&#xD;
          -  women with no health or social security coverage&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>43 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BOUET Pierre Emmanuel</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Angers</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BOUET Pierre-Emmanuel, MD</last_name>
    <phone>+33241353637</phone>
    <email>pierreemmanuel.bouet@chu-angers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>CORROENNE Romain</last_name>
    <phone>+33241353637</phone>
    <email>corroenne.romain@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CORROENNE ROMAIN</last_name>
      <phone>0650678034</phone>
      <phone_ext>33</phone_ext>
      <email>corroenne.ROMAIN@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>BOUET PIERRE EMMANUEL</last_name>
      <phone>0241353647</phone>
      <email>PierreEmmanuel.BOUET@chu-angers.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>March 24, 2018</study_first_submitted>
  <study_first_submitted_qc>May 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2018</study_first_posted>
  <last_update_submitted>August 30, 2018</last_update_submitted>
  <last_update_submitted_qc>August 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

